This study compares the pharmaceutical costs of ovarian hyperstimulation with either rFSH-alfa or rFSH-beta, using a pen device, in the most common settings of clinical practice in Spain. For this purpose, in the first place, protocols commonly used for the treatment of IVF/ICSI and IUI patients were reflected with decision trees, showing starting rFSH doses and their possible subsequent modifications, the probability of making these modifications, and the duration of the treatment. These decision trees were then used to calculate the expected costs of a treatment cycle for each of the protocols and each of the two drugs. For all analyzed protocols the expected cost turned out to be lower for rFSH-beta. Depending on the specific protocol, the difference in cost per cycle lay between €43 and € 292€ implying potential savings on drug costs of 6.8% to 17.5% when using rFSH-beta instead of rFSH-alfa.
|Journal||Revista Iberoamericana de Fertilidad y Reproduccion Humana|
|Publication status||Published - 1 Sep 2010|
- Assisted reproduction
- Optimal prescription
- Ovarian stimulation